CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our target price to $369 from $325, based on 32x our FY 27 EPS estimate, with the multiple reflecting a healthy premium to the historical three-year average of 23x, given our positive outlook on the company's trajectory and recent strong performance. We increase our FY 26 and FY 27 EPS estimates to $10.14 (from $8.87) and $11.53 (from $10.17), led by Q2's impressive margin expansion and favorable business mix shift. Record orders of $2B+ grew 56% Y/Y, significantly outpacing 31% revenue growth and building substantial backlog visibility. Growth is broad-based: CSG revenue grew 35% Y/Y, EISG expanded 24%, and ADG posted record orders due to defense modernization priorities. Operating leverage is translating strong top-line performance into accelerating cash generation (record $472M in FCF). We believe the market has priced in the company's accelerated growth trajectory and enhanced earnings power, with shares up 69% YTD, resulting in a balanced risk/reward outlook.